Mumbai, Feb. 28 -- The drug-device combination will be marketed in the U.K. under the brand names Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda).

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., earlier this year, making Biocon the first generics company to obtain approval for gLiraglutide in a major regulated market.

Siddharth Mittal, chief executive officer and managing director, Biocon, said: "The launch of our gLiraglutide for diabetes and obesity in the U.K. marks a significant milestone for Biocon.

The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need.

We...